Atlanta Fibroid Center

What Atlanta Fibroid Center does

Atlanta Fibroid Center is a privately held, founder-owned outpatient medical practice headquartered in Smyrna, Georgia, founded in 1991 by interventional radiologist Dr. John C. Lipman, MD, FSIR. The practice specializes in the non-surgical treatment of symptomatic uterine fibroids and adenomyosis, primarily through Uterine Fibroid Embolization (UFE) — a catheter-based procedure in which embolic particles are delivered under real-time angiographic guidance to block blood flow to fibroid tissue — and the related Uterine Artery Embolization (UAE) for adenomyosis. Diagnostic pelvic MRI, performed on in-house high-resolution 3T-class equipment, supports both initial diagnosis and post-procedure follow-up. The center also operates a second clinic in Lawrenceville, GA, giving it two locations across the Atlanta metropolitan area. Dr. Lipman has performed over 10,000 UFE procedures, making the center one of the highest-volume dedicated fibroid-embolization practices in the United States; Dr. Sima Banerjee, MD, has joined as a second interventional radiologist to expand clinical capacity.

The business model is fee-for-service healthcare revenue from a direct-to-consumer patient base: revenue is generated from one-time UFE/UAE procedures, professional fees for consultations, and diagnostic MRI services, with payment flowing through commercial insurance, Medicare, and self-pay. Patient acquisition runs through a digital marketing engine (website, Facebook, Instagram, YouTube, TikTok, X, email, and SEO-optimized educational content), supplemented by inbound referrals from OB/GYNs who do not perform UFE and by patients seeking second opinions after being offered hysterectomy or myomectomy. Marketing messaging is consistently positioned around uterus preservation, faster recovery (4-5 days vs. 4-6 weeks for surgery), and the 90% efficacy rate of UFE.

The competitive profile rests on a small set of durable assets: the founder's individual case volume and reputation, a dedicated angiographic suite described as the only one of its kind in Atlanta, an exclusive clinical focus on fibroids and adenomyosis rather than general interventional radiology, and the 2025 Best of Georgia Physician Practice award. The practice carries no external investors, no parent company, and no disclosed subsidiaries, and operates as a single specialty group with two physicians across two Georgia clinics.

Name

Atlanta Fibroid Center

Legal name

Atlanta Fibroid Center

Website

https://atlii.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

Atlanta Fibroid Center is a private, founder-owned outpatient practice in Smyrna and Lawrenceville, GA, specializing in non-surgical UFE and UAE treatment of uterine fibroids and adenomyosis. Founded in 1991 by Dr. John Lipman (10,000+ procedures), it serves women seeking uterus-preserving alternatives to hysterectomy.

Ownership category

akta.pro rank

Product category

Interventional Radiology / Women's Health Services

NAICS

Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Obstetrics & Gynecology (OB/GYN) Clinics (HLAFAJAA)

akta.pro secondary industry

Pain Management & Interventional Procedure Centers (HLAFAIAH)

Keywords

• Uterine fibroid treatment
• Fibroid embolization
• Adenomyosis treatment
• Interventional radiology services
• Pelvic MRI imaging

Headquarters

HQ city

Smyrna

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. UFE/UAE Procedures: Revenue generated from performing uterine fibroid embolization and uterine artery embolization procedures. These are one-time interventional radiology procedures performed in the outpatient facility.
2. Medical Consultations: Revenue from initial consultations and follow-up appointments with Dr. Lipman and Dr. Banerjee to discuss symptoms, review MRI results, and determine treatment options.
3. Diagnostic Imaging: Revenue from pelvic MRI imaging services used for diagnosis and post-procedure follow-up to confirm treatment success.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Core offering

Atlanta Fibroid Center provides non-surgical, minimally invasive treatment of uterine fibroids and adenomyosis through Uterine Fibroid Embolization (UFE) and Uterine Artery Embolization (UAE) procedures performed by board-certified interventional radiologists in an outpatient setting. Services also include diagnostic pelvic MRI imaging, initial consultations, and follow-up care. Procedures preserve the uterus and fertility, are covered by most insurance plans including Medicare, and require 4–5 days recovery compared to 4–6 weeks for surgical alternatives.

Product overview

Atlanta Fibroid Center offers a focused portfolio of non-surgical treatments for women's reproductive health conditions. The center's primary offerings are Uterine Fibroid Embolization (UFE) for treating fibroids and Uterine Artery Embolization (UAE) for adenomyosis—both minimally invasive, uterus-preserving procedures performed by interventional radiologists. The center also provides diagnostic Pelvic MRI Imaging services. All treatments are outpatient procedures that preserve the uterus and fertility, distinguishing them from traditional surgical options like hysterectomy and myomectomy.

Differentiator

Problem solved

Functional benefit

Products and services

• Uterine Fibroid Embolization (UFE) A non-surgical, minimally invasive outpatient interventional radiology procedure that treats uterine fibroids by blocking blood flow to the fibroids using catheter-delivered embolic particles, causing them to shrink and die. The procedure takes approximately 45 minutes, preserves the uterus, and has a 90% success rate with a 4–5 day recovery time. Indicated for women with symptomatic fibroids seeking an alternative to hysterectomy or myomectomy.
• Uterine Artery Embolization (UAE) A non-surgical, catheter-based interventional radiology procedure that treats adenomyosis by cutting off the blood supply to adenomyosis tissue using embolic particles, causing the tissue to shrink and symptoms to resolve. The procedure has an approximately 70–80% success rate, preserves the uterus and fertility, and is intended for women with symptomatic adenomyosis.
• Pelvic MRI Imaging High-resolution pelvic MRI imaging used for accurate diagnosis of uterine fibroids and adenomyosis. Provides detailed views of fibroid size, location, and number, as well as adenomyosis tissue characteristics — considered the gold standard for pelvic imaging and able to identify conditions that may be missed by ultrasound. Used for treatment planning and post-procedure follow-up.

Quantifiable outcome

• 90% effectiveness rate in treating fibroids and reducing symptoms
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• USA Fibroid Centers: A national multi-site chain operating dedicated UFE centers. Directly competes on the same non-surgical uterine fibroid embolization procedure, though with a broader geographic footprint and scaled brand versus Atlanta Fibroid Center's single-metro concentration.
• Fibroid Institute: Specialty practice offering UFE for fibroid treatment with a similar single-modality focus. Comparable on procedure mix, direct-to-consumer marketing, and physician-specialist positioning, though based in a different metro market.

Regional players

• Charlotte Fibroid Center: Dedicated UFE practice operating in the Carolinas. Same procedure focus and DTC acquisition model, but in a non-overlapping Southeast metro that competes for the same regional patient pool.
• Houston Fibroids: Interventional radiology practice specializing in uterine fibroid embolization in a different regional market. Comparable clinical focus and direct-to-patient positioning; competes for inbound patients traveling for specialized fibroid care.
• New York Fibroid Care: Northeast-based dedicated UFE practice. Same single-procedure specialization and patient education-led DTC model as Atlanta Fibroid Center, operating in a different geography.

Broad incumbents

• Mayo Clinic: Large multi-specialty academic health system that performs uterine fibroid embolization within interventional radiology. Provides a tertiary-care alternative for complex or recurring cases and represents the broad-incumbent ceiling against which dedicated UFE centers must differentiate on access and patient experience.
• Cleveland Clinic: Major multi-specialty health system with a robust interventional radiology capability that performs UFE. Comparable procedural capability but embedded in a general hospital setting rather than a focused outpatient women's health model.

Others

• Society of Interventional Radiology (SIR): The professional society for interventional radiologists, of which Dr. Lipman is a Fellow. Sets clinical standards, drives payer coverage decisions, and funds fibroid/adenomyosis research (including Dr. Lipman's documented donation to SIR Foundation), shaping the ecosystem in which all UFE practices operate.
• Boston Scientific: Medical device manufacturer producing embolization products used in UFE procedures. Not a competitor but a critical supplier whose product pipeline, pricing, and reimbursement support directly affect the cost structure and clinical capability of every UFE practice.
• Merit Medical Systems: Manufacturer of embolic agents and interventional radiology consumables used in UFE/UAE. Functions as an enabling supplier to fibroid embolization rather than a direct competitor, but influences procedure economics and availability.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/DrLipman1
• YouTubeyoutube.com/@Atlii
• Facebookfacebook.com/profile.php?id=61559734317717
• Instagraminstagram.com/atlantafibroidcenter
• TikToktiktok.com/@atlanta.fibroid.center?is_from_webapp=1&sender_device=pc
• LinkedInlinkedin.com/company/atlanta-interventional-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atlanta Fibroid Center